A phase 2 study of decitabine administered daily for 5 days every 4 weeks to adults with advanced-stage myelodysplastic syndromes

Trial Profile

A phase 2 study of decitabine administered daily for 5 days every 4 weeks to adults with advanced-stage myelodysplastic syndromes

Completed
Phase of Trial: Phase II

Latest Information Update: 17 May 2013

At a glance

  • Drugs Decitabine (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Registrational; Therapeutic Use
  • Acronyms ADOPT
  • Most Recent Events

    • 11 Mar 2010 Results from this trial were used to support US FDA approval of the 5-day decitabine regimen in patients with myelodysplastic syndromes, as reported by Eisai.
    • 09 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 01 Jul 2008 Eisai plans to submit an sNDA with the US FDA for a 5-day regimen of decitabine based on the DACO-020 trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top